Arrowhead Pharmaceuticals, Inc. (ARWR) stock analysis

On Oct 14, 2026, our model rated Arrowhead Pharmaceuticals, Inc. (ARWR) WEAK BUY with 26% confidence at a price of $58.13. That means the signals lean positive, but they are mixed, so conviction is low.

Technical picture

The 14-day RSI is 19, below 30, which is oversold territory: sellers have pushed hard recently. Oversold stocks often bounce, but they can stay weak for a while.

MACD is below its signal line, so short-term momentum is pointing down.

The price is below both its 50-day and 200-day moving averages, the classic picture of a downtrend.

Volume is about normal (1.0x the 20-day average).

Trend structure and money flow

Market structure: bullish structure intact, no fresh break.

The most recent swing high is $95.49 and the swing low is $54.02; traders often treat these as resistance and support.

Fundamentals

The company reports a profit margin of -47.8% and revenue growth of +171.0%.

In its latest quarter it earned $-1.36 per share, which missed the $-1.23 analysts expected, with revenue +171.0% year over year.

Wall Street's average rating is 1.4 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $107.23.

The next earnings report is expected around Nov 24, 2026; prices often move sharply around earnings.

Trade plan from the model

The model's long / bullish plan uses an entry near $58.77, a target of $63.12 (+7.4%) and a stop-loss at $54.24 (-7.7%).

That is a reward-to-risk ratio of about 1.0 to 1: the potential loss is bigger than the gain, a weak setup.

The plan has a time limit: reassess by Oct 24, 2026 whatever the price does.

The model's one-paragraph read

Leans BUY — composite score +0.26 (WEAK BUY). Technicals: RSI 19.4, MACD bearish, price below SMA50. Fundamentals: margin -47.8%, revenue growth 171.0%. Financial results: YoY revenue +171.0%, last EPS surprise -10.6%, next earnings 2026-11-24. Smart Money Concepts: bullish structure intact, no fresh break. FinGPT news read: positive. Memory: 1 prior look(s). Suggested levels: entry $58.77, target $63.12, stop-loss $54.24, exit by 2026-10-24 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).

Past ratings for ARWR

"Move since" compares each call's price with the latest analysed price.

Recent news on ARWR

• Oct 14, 2026: Arrowheads Alzheimers disease drug reduces tau in Phase I/IIa trial (Clinical Trials Arena)
• Oct 14, 2026: Arrowheads Alzheimers Drug Shows Sharp Reduction In Disease-Linked Protein In Early Trial Heres What Investors Need To Know (Stocktwits)
• Oct 14, 2026: Arrowhead jumps as breakthrough Alzheimers drug clears brain barrier (Investing.com)
• Oct 14, 2026: Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers (Business Wire)

Other Healthcare stocks we cover

ASTH · ATEC · ATRC · BCRX · BDX · BIIB · BMY · BSX · CMPS · CNC · COO · CRL

Frequently asked questions

Is ARWR a buy right now?

As of Oct 14, 2026, our automated model rates Arrowhead Pharmaceuticals, Inc. (ARWR) WEAK BUY with 26% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.

What is the price target for ARWR?

The model's most recent plan targets $63.12 with a stop-loss at $54.24, from an entry near $58.77.

When does Arrowhead Pharmaceuticals, Inc. report earnings next?

The next earnings report is expected around Nov 24, 2026.

What does a WEAK BUY rating mean?

A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.